Grifols, S.A. (GRFS)
| Market Cap | 6.61B +18.3% |
| Revenue (ttm) | 8.83B +4.3% |
| Net Income | 472.00M +156.1% |
| EPS | 0.69 +156.5% |
| Shares Out | 680.58M |
| PE Ratio | 14.00 |
| Forward PE | 9.24 |
| Dividend | $0.14 (1.73%) |
| Ex-Dividend Date | Aug 12, 2025 |
| Volume | 758,790 |
| Open | 8.13 |
| Previous Close | 8.25 |
| Day's Range | 8.00 - 8.25 |
| 52-Week Range | 6.19 - 11.14 |
| Beta | 1.19 |
| Analysts | Hold |
| Price Target | 10.15 (+23.18%) |
| Earnings Date | Jul 28, 2022 |
About GRFS
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as wel... [Read more]
Financial Performance
In 2025, Grifols's revenue was 7.52 billion, an increase of 4.33% compared to the previous year's 7.21 billion. Earnings were 402.00 million, an increase of 156.05%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for GRFS stock is "Hold." The 12-month stock price target is $10.15, which is an increase of 23.18% from the latest price.
News
Grifols (GRFS) Faces Health Canada's New Regulations After Inspection Failures
Grifols (GRFS) Faces Health Canada's New Regulations After Inspection Failures
Health Canada slaps new conditions on plasma donation company Grifols, still reviewing 2 Manitoba deaths
Health Canada has slapped new terms and conditions on all of a company's paid plasma centres after multiple failed inspections where the regulator found "recurring, systemic deficiencies."
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates
OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada are calling for the closure of Grifols facilities in the wake of two deaths in Winnipeg of people wh...
Grifols (GRFS) Considers U.S. IPO Amid Strategic Shift
Grifols (GRFS) Considers U.S. IPO Amid Strategic Shift
Grifols (GRFS) Plans U.S. IPO for Biopharma Business
Grifols (GRFS) Plans U.S. IPO for Biopharma Business
Grifols Plans IPO of U.S. Biopharma Business
Grifols (GRFS) Considers US IPO for Biopharma Unit
Grifols (GRFS) Considers US IPO for Biopharma Unit
Grifols (GRFS) Contemplates U.S. Biopharma Unit IPO
Grifols (GRFS) Contemplates U.S. Biopharma Unit IPO
Grifols approves IPO of its US biopharma business
Healthcare company Grifols said on Tuesday it has approved a U.S. initial public offering of its U.S. biopharma business.
Grifols (GRFS) Reveals Advancements in Early Parkinson's Detection
Grifols (GRFS) Reveals Advancements in Early Parkinson's Detection
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease
BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today shared proof-of-conc...
Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following reports of deaths, harm, non-compliance
TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- The Ontario and Manitoba Health Coalitions held a press conference this morning to respond to a report from CBC about two patients who died in Winnipeg afte...
Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following reports of deaths, harm, non-compliance
TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- The Ontario and Manitoba Health Coalitions held a press conference this morning to respond to a report from CBC about two patients who died in Winnipeg af...
Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols' Sites
WINNIPEG, Manitoba and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- What: Spokespeople from the Manitoba Health Coalition and Ontario Health Coalition will respond to the sad news of two deaths of paid...
Grifols SA (GRFS) (Full Year 2025) Earnings Call Highlights: Strong Revenue Growth Amidst ...
Grifols SA (GRFS) (Full Year 2025) Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges
Full Year 2025 Grifols SA Earnings Call Transcript
Full Year 2025 Grifols SA Earnings Call Transcript
Grifols (GRFS) Projects Strong Financial Performance by 2026
Grifols (GRFS) Projects Strong Financial Performance by 2026
Grifols (GRFS) Exceeds Revenue Expectations and Gains Credit Rating Upgrades
Grifols (GRFS) Exceeds Revenue Expectations and Gains Credit Rating Upgrades
Grifols doubles net profit in 2025, driven by revenues
Spanish drugmaker Grifols reported on Thursday a net profit of 402 million euros ($473.96 million) for 2025, more than double what it recorded the previous year, driven by revenues of 7.5 billion euro...
Spanish court summons Gotham City founder in Grifols share price probe
Spain's High Court on Thursday summoned the founder of U.S.-based short seller Gotham City Research, Daniel Yu, to testify over allegations his company disseminated misleading information about pharma...
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology
Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and...
Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF...
US court finds enough evidence to proceed with Grifols lawsuit against Gotham City
A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on...
Grifols says on course to meet 2025 outlook as net profit triples
Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.
IBL International collaborates with Grifols on advanced biomarker panels
MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a...